Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes

Berra, Cesare; Resi, Veronica; Mirani, Marco; Folini, L.; Rossi, Antônio; Solerte, Sebastiano Bruno; Fiorina, Paolo

doi:10.1016/j.phrs.2020.104996

Cited by 19 publications

(14 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a previous long-term study, patients who were switched from another GLP-1 RA or DPP4 inhibitor to dulaglutide showed significant reduction of the HbA1c, although the degree of reduction was lower than that in patients who were receiving biguanides, thiazolidinediones, sulfonylureas, or insulin, either alone or in combination [29]. However, there are no studies on the effect of switching from DPP4 inhibitors or other GLP-1 RAs to dulaglutide on the immediate effects of the latter on the BG levels so far.…”

Section: Discussionmentioning

confidence: 86%

“…There are no previous reports on the influence of diabetic complications on the glucose-lowering effect of dulaglutide. Patients without diabetic complications are likely to have a shorter duration of diabetes, but the results cannot be interpreted clearly, as the influence of the duration of diabetes on the reduction of HbA1c reported by previous studies is conflicting [18,28,29].…”

Section: Discussionmentioning

confidence: 90%

“…According to two previous studies, the duration of diabetes was not associated with the change in the HbA1c achieved with dulaglutide treatment [18,28], but a third study showed that patients with a shorter duration of diabetes showed greater degree of reduction of the HbA1c following dulaglutide treatment [29]. In the present study, the duration of diabetes was not related to the D BG levels, but subjects without a history of diabetic retinopathy and cerebrovascular disease showed greater D SD of the 6-point BG levels and D fasting BG levels, respectively.…”

Section: Discussionmentioning

confidence: 98%

See 2 more Smart Citations

Immediate Glucose-Lowering Effect After the First Administration of Dulaglutide: A Retrospective, Single-Center, Observational Study

et al. 2021

View full text Add to dashboard Cite

Introduction: Dulaglutide is a long-acting glucagon-like peptide 1 receptor agonist that is administered once weekly for the treatment of type 2 diabetes. However, the immediate glucose-lowering effect of dulaglutide after the first administration and the factors affecting the efficacy of the drug remain unclear. Methods: This study was a retrospective and observational study of 80 subjects with type 2 diabetes conducted in a hospitalized setting. The changes (D) in the blood glucose (BG) levels at six time points (6-point BG levels) from the baseline (day -1) to the day after the first administration of 0.75 mg of dulaglutide (day 1) were evaluated. The associations of the D 6point BG levels with the patients' characteristics and laboratory data were also analyzed. Results: Significant reduction of the fasting BG, preprandial BG, postprandial BG, and standard deviation (SD) of the 6-point BG levels was

show abstract

Section: Discussionmentioning

confidence: 86%

Section: Discussionmentioning

confidence: 90%

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Immediate Glucose-Lowering Effect After the First Administration of Dulaglutide: A Retrospective, Single-Center, Observational Study

et al. 2021

View full text Add to dashboard Cite

show abstract

“… 17 Similarly, two other recent studies found that treatment with dulaglutide was discontinued by approximately 15% of patients within the first year of treatment. 18 , 19 It is also worth considering that differences may be related to the development of simpler and easier devices, and less frequent dosing regimens being recommended for certain GLP‐1 RAs over time.…”

Section: Discussionmentioning

confidence: 99%

The Real‐WorldObservational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months

Guerci¹,

Giorgino

Sapin³

et al. 2022

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aims: The primary objective of the TROPHIES observational study is to estimate the duration of treatment on dulaglutide or liraglutide without a significant treatment change by 24 months in patients with type 2 diabetes (T2D) initiating their first injectable treatment with these glucagon-like peptide-1 receptor agonists (GLP-1 RAs). This manuscript presents 12-month interim data. Materials and Methods: TROPHIES is a prospective, non-comparative, observational study of patients with T2D in Europe, naïve to injectable antihyperglycaemic treatments and initiating dulaglutide or liraglutide. Data on clinical characteristics, GLP-1 RA persistence and treatment patterns of glucose-lowering medication were collected at initiation of first injectable therapy and by 12 months. Results: By 12 months, 1014 dulaglutide and 991 liraglutide patients were eligible across France, Germany and Italy. Both cohorts presented a high probability [95% confidence interval (CI)] of GLP-1 RA persistence [dulaglutide, 0.88 (0.86 to 0.90); liraglutide, 0.83 (0.80 to 0.85)] and reduction in mean glycated haemoglobin percentage (95% CI) from baseline [dulaglutide, À1.18 (À1.27 to À1.08); liraglutide, À1.15 (À1.26 to À1.05)] with 48.2% of dulaglutide and 41.2% of liraglutide patients reaching their individualized glycated haemoglobin percentage target set by the physician at baseline. Mean weight (95% CI) change from baseline was À3.2 kg (À3.6 to À2.8) for dulaglutide and À3.4 kg (À3.9 to À3.0) for liraglutide. Slight changes in concomitant medications were observed compared with baseline. * Joint first author because of equal contributions.

show abstract

“…The decrease of blood glucose, induced by GLP-1 receptor agonists, can be affected by baseline glucose level. For example, in the study of Berra et al [ 100 ], patients with high glycated haemoglobin (HbA1c) at baseline saw its greatest reduction after 6 months of once-a-week administration of dulaglutide. The low baseline of HbA1c and the short duration of diabetes were important predictors of the achievement of HbA1c ≤ 7.0%.…”

Section: Treatment Of Type 2 Diabetes Mellitusmentioning

confidence: 99%

Pharmaceutical Drugs and Natural Therapeutic Products for the Treatment of Type 2 Diabetes Mellitus

et al. 2021

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) is the most widespread form of diabetes, characterized by chronic hyperglycaemia, insulin resistance, and inefficient insulin secretion and action. Primary care in T2DM is pharmacological, using drugs of several groups that include insulin sensitisers (e.g., biguanides, thiazolidinediones), insulin secretagogues (e.g., sulphonylureas, meglinides), alpha-glucosidase inhibitors, and the newest incretin-based therapies and sodium–glucose co-transporter 2 inhibitors. However, their long-term application can cause many harmful side effects, emphasising the importance of the using natural therapeutic products. Natural health substances including non-flavonoid polyphenols (e.g., resveratrol, curcumin, tannins, and lignans), flavonoids (e.g., anthocyanins, epigallocatechin gallate, quercetin, naringin, rutin, and kaempferol), plant fruits, vegetables and other products (e.g., garlic, green tea, blackcurrant, rowanberry, bilberry, strawberry, cornelian cherry, olive oil, sesame oil, and carrot) may be a safer alternative to primary pharmacological therapy. They are recommended as food supplements to prevent and/or ameliorate T2DM-related complications. In the advanced stage of T2DM, the combination therapy of synthetic agents and natural compounds with synergistic interactions makes the treatment more efficient. In this review, both pharmaceutical drugs and selected natural products, as well as combination therapies, are characterized. Mechanisms of their action and possible negative side effects are also provided.

show abstract

Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes

Cited by 19 publications

References 33 publications

Immediate Glucose-Lowering Effect After the First Administration of Dulaglutide: A Retrospective, Single-Center, Observational Study

Immediate Glucose-Lowering Effect After the First Administration of Dulaglutide: A Retrospective, Single-Center, Observational Study

The Real‐WorldObservational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months

Pharmaceutical Drugs and Natural Therapeutic Products for the Treatment of Type 2 Diabetes Mellitus

Contact Info

Product

Resources

About